Press Releases April 29, 2026 04:43 PM

Hawthorn Bancshares Announces Cash Dividend

Hawthorn Bancshares declares quarterly cash dividend of $0.21 per share

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
HWBK

Hawthorn Bancshares, Inc. announced that its Board of Directors has approved a quarterly cash dividend of $0.21 per common share, payable on July 1, 2026, to shareholders of record as of June 15, 2026. The company is a Missouri-based bank holding company with various locations serving families and businesses.

Hawthorn Bancshares Announces Cash Dividend
HWBK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Hawthorn Bancshares declared a $0.21 per share quarterly cash dividend.
  • Dividend payable on July 1, 2026, to shareholders of record by June 15, 2026.
  • The company operates multiple bank locations in Missouri, serving the financial sector across regions including Kansas City metro area.

JEFFERSON CITY, Mo., April 29, 2026 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.21 per common share. The dividend is payable on July 1, 2026 to shareholders of record at the close of business on June 15, 2026.

About Hawthorn Bancshares, Inc.

Hawthorn Bancshares, Inc., a bank holding company headquartered in Jefferson City, Missouri, is the parent company of Hawthorn Bank, which has served families and businesses for more than 160 years. Hawthorn Bank has multiple locations, including in the greater Kansas City metropolitan area, Jefferson City, Columbia, Springfield, and Clinton.

Contact:

Hawthorn Bancshares, Inc.
Brent M. Giles
Chief Executive Officer
TEL: 573.761.6100
www.HawthornBancshares.com

Statements made in this press release that suggest the Company's or management's intentions, hopes, beliefs, expectations, or predictions of the future include "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. It is important to note that actual results could differ materially from those projected in such forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those projected in such forward-looking statements is contained from time to time in the Company's quarterly and annual reports filed with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this communication, and the Company disclaims any obligation to update any forward-looking statement or to publicly announce the results of any revisions to any of the forward-looking statements included herein, except as required by law.


Risks

  • Dividend declarations are subject to board approval and prevailing economic conditions, which could change.
  • Forward-looking statements indicate potential variability in actual results compared to expectations.
  • Macroeconomic factors and banking regulations could impact future earnings and dividend sustainability.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026